The Effect of TCM Syndrome and Th17/Treg Cells Immunomodulatory of Yiqi Jiedu Compound on Patients with Myasthenia Gravis
- VernacularTitle:益气解毒复方对重症肌无力患者中医证候影响及Th17/Treg细胞免疫调节作用
- Author:
Yalin LIU
1
,
2
;
Yuanhua WU
;
Qing GUO
;
Youde CAI
;
Shanshan WANG
;
Chen LI
;
Qiansong HE
Author Information
- Keywords: Yiqi jiedu compound; Myasthenia gravis; TCM syndrome integral; Balance of Th17/Treg
- From: World Science and Technology-Modernization of Traditional Chinese Medicine 2023;25(6):2203-2208
- CountryChina
- Language:Chinese
- Abstract: Objective To observe the effects of Yiqi Jiedu Compound on TCM syndrome score and immune regulation of Th17/Treg cells in peripheral blood of patients with myasthenia gravis.Methods 63 patients with myasthenia gravis were randomly divided into the control group(n=31)and the treatment group(n=32).The control group was given the basic treatment of pyridostigmine bromide and glucocorticoid and so on,and the treatment group was given Yiqi Jiedu Compound based on the control group.The two groups were treated for 12 weeks.Clinical efficacy was observed,TCM syndrome scores were statistically analyzed,and the expression levels were detected,which Th17/Treg cells,Foxp3/RORγ t gene and IL-6 and IL-17 cytokines in peripheral blood of patients in both groups before and after treatment.Results After 12 weeks of treatment,compared with the control group,the TCM syndrome score of patients in the treatment group was significantly decreased(P<0.05),and the expression of Foxp3 and Treg genes in peripheral blood was promoted(P<0.05),and the expression of Th17 and Treg cells and IL-6 and IL-17 cytokines in peripheral blood was decreased(P<0.05).Conclusion Yiqi Jiedu Compound may regulate the immune balance of Th17/Treg cells by affecting the differentiation of Th17 and Treg cells in peripheral blood and the expression levels of transcription factors RORγ t and Foxp3 genes and related cytokines,thus achieving the effect of myasthenia gravis treatment.
